synovitis: ['Inflammation of the SYNOVIAL MEMBRANE [ MeSH ]']
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
328 |
4. Check minimum number of eventsNone |
328 |
5. Include endpointsNone |
328 |
6. Filter based on genotype QC (FinnGen only) |
328 |
Control definitions (FinnGen only)
- Control exclude
- M13_SOFTTISSUE
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- M67
- Name in latin
- Synovitis transitoria
Similar endpoints
↥List of similar endpoints to
Transient synovitis
based on the number of shared cases.
Similar with more cases:
- Disorders of synovium and tendon
- Soft tissue disorders
- Diseases of the musculoskeletal system and connective tissue
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 4739 | 1722 | 3013 |
| Only index persons | 3886 | 1464 | 2422 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.07 | 0.05 | 0.08 |
| Only index persons | 0.08 | 0.05 | 0.09 |
| Median age at first event (years) | |||
| Whole population | 6.89 | 8.17 | 6.11 |
| Only index persons | 8.02 | 10.50 | 6.51 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 328 | 191 | 137 |
| Unadjusted period prevalence (%) | 0.06 | 0.07 | 0.06 |
| Median age at first event (years) | 23.78 | 30.04 | 15.06 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 286
- Matched controls
- 2859
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
M67.3
ICD-10 Finland
Transient synovitis
+∞
323.0
286
*
M67.4
ICD-10 Finland
Ganglion
31.6
31.2
41
15
M25.5
ICD-10 Finland
Pain in joint
4.9
28.3
112
330
NDM40
NOMESCO Finland
Discission of sheath of tendon of wrist or hand
+∞
20.0
19
*
M65.3
ICD-10 Finland
Trigger finger
27.6
17.2
23
9
NDM20
NOMESCO Finland
Excision of synovial ganglion of wrist or hand
180.1
16.7
17
*
M13.9
ICD-10 Finland
Arthritis, unspecified
7.8
16.3
38
55
NBG15
NOMESCO Finland
Acromioplastia, arthroscopic
40.5
15.6
19
5
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
4.8
13.9
48
115
NF1AE
NOMESCO Finland
Hip joint ultrasound examination
13.0
13.9
24
20
L04AX03
ATC
methotrexate; systemic (immunosuppressants)
5.3
13.2
41
87
TNX10
NOMESCO Finland
Arthrocentesis, unspecified region, unspecified region
6.2
12.9
35
63
M79.6
ICD-10 Finland
Pain in limb
3.0
12.8
86
355
NGA30
NOMESCO Finland
Exploration of knee joint, arthroscopic
10.0
12.8
25
27
NGF15
NOMESCO Finland
Total synovectomy of knee, arthroscopic
45.2
11.0
13
*
313
Kela drug reimbursment
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab, tocilizumab and ustekinumab (rheumatoid diseases)
9.1
10.8
22
26
N06AA09
ATC
amitriptyline; systemic
6.4
10.7
28
48
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
5.4
10.7
32
65
M65.9
ICD-10 Finland
Synovitis and tenosynovitis, unspecified
16.9
10.5
16
10
281
Kela drug reimbursment
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab and tocilizumab
9.4
10.5
21
24
M01AH05
ATC
etoricoxib; oral
2.3
10.3
143
867
M19.0
ICD-10 Finland
Primary arthrosis of other joints
6.5
10.3
26
43
NGF00
NOMESCO Finland
Excision of plica of synovy of knee
12.8
10.0
17
14
NGF35
NOMESCO Finland
Plastic operation of joint cartilage of knee
10.6
9.7
18
18
M17.1
ICD-10 Finland
Other primary gonarthrosis
3.6
9.6
44
137
M75.1
ICD-10 Finland
Rotator cuff syndrome
3.7
9.3
41
123
M02AA07
ATC
piroxicam; topical
2.5
9.0
79
375
M05.8
ICD-10 Finland
Other seropositive rheumatoid arthritis
7.2
9.0
21
31
M75.4
ICD-10 Finland
Impingement syndrome of shoulder
11.2
8.9
16
15
N02AX02
ATC
tramadol; systemic, rectal
2.4
8.9
88
444
M65.8
ICD-10 Finland
Other synovitis and tenosynovitis
16.9
8.6
13
8
NGF25
NOMESCO Finland
Operation for osteochondritis of knee, arthroscopic
5.5
8.1
23
45
N02AJ06
ATC
codeine and paracetamol; systemic
2.2
7.9
92
500
A07EC01
ATC
sulfasalazine; oral, rectal
4.0
7.9
31
85
M01AC06
ATC
meloxicam; systemic, rectal
2.4
7.9
77
386
SPAT1153
SPAT
Removal of sutures
2.4
7.6
73
362
L88
ICPC
Rheumatoid/seropositive arthritis
6.8
7.5
18
28
P01BA02
ATC
hydroxychloroquine; oral
4.4
7.4
26
64
L04AA13
ATC
leflunomide; oral
11.3
7.4
13
12
G56.0
ICD-10 Finland
Carpal tunnel syndrome
3.5
7.2
32
98
N06AX21
ATC
duloxetine; oral
3.7
7.0
29
84
ZXA00
NOMESCO Finland
Right side
2.5
7.0
60
279
NF1AA
NOMESCO Finland
Hip X-ray examination
4.8
6.9
22
49
M01AE02
ATC
naproxen; oral, rectal
1.9
6.9
171
1242
NG1AA
NOMESCO Finland
Knee X-ray examination without contrast
3.3
6.6
32
105
M23.8
ICD-10 Finland
Other internal derangements of knee
6.0
6.6
17
30
M17.5
ICD-10 Finland
Other secondary gonarthrosis
14.7
6.4
10
7
M08.4
ICD-10 Finland
Pauciarticular juvenile arthritis
11.4
6.3
11
10
M01AH01
ATC
celecoxib; oral (coxibs)
3.0
6.3
36
132
NGF10
NOMESCO Finland
Total synovectomy of knee, open
+∞
6.3
6
*
M17.0
ICD-10 Finland
Primary gonarthrosis, bilateral
3.6
6.1
26
77
R01BA52
ATC
pseudoephedrine, combinations; oral
2.2
6.1
67
349
L15
ICPC
Knee symptom/complaint
2.2
6.0
63
320
M23.2
ICD-10 Finland
Derangement of meniscus due to old tear or injury
3.3
6.0
29
95
M01AX17
ATC
nimesulide; oral
2.6
6.0
42
175
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
21
29
7.67
14.57
2.0
1.4
—
—
—
0
0
69
301
2.64
10.55
1.3
1.2
15.1
12.0
u/ml
0.08
24
117
229
1670
2.23
10.04
6.2
3.4
9.7
8.9
mm/h
0.40
224
1536
195
1398
1.97
8.16
13.3
8.9
3.9
3.9
e9/l
0.20
179
1198
65
326
2.24
7.16
1.3
1.2
29.4
31.6
iu/ml
0.07
17
100
172
1225
1.85
6.91
6.3
4.8
6.5
6.4
mmol/l
0.09
155
1117
220
1697
1.90
6.81
7.7
6.4
80.0
82.1
u/l
0.21
211
1582
157
1113
1.79
6.19
4.9
3.1
0.0
0.0
estimate
0.00
25
214
157
1126
1.76
5.85
4.9
3.1
0.0
0.0
estimate
0.00
28
213
128
867
1.78
5.80
4.4
3.2
—
—
—
0
0
13
29
4.63
5.56
1.8
1.4
—
—
—
0
0
89
549
1.85
5.44
5.6
3.2
1.0
1.0
kg/l
0.07
15
79
153
1114
1.70
5.22
6.1
4.3
0.0
0.0
estimate
0.50
28
226
74
453
1.82
4.57
2.9
1.7
1.0
1.1
mg/l
0.20
57
332
289
2561
2.08
4.54
16.5
10.0
22.4
21.9
mg/l
0.07
222
1867
96
639
1.71
4.43
2.7
2.9
14.1
28.1
ng/l
2.02
57
355
90
592
1.72
4.32
4.9
3.4
0.0
0.0
estimate
0.80
28
214
106
729
1.67
4.32
4.9
3.1
—
—
—
0
0
115
812
1.64
4.21
7.0
4.8
36.8
37.0
g/l
0.15
110
765
236
1991
1.66
4.08
5.5
4.3
37.8
37.9
mmol/mol
0.06
225
1880
9
15
6.14
3.84
8.9
2.3
—
—
—
0
0
152
1184
1.53
3.50
3.2
2.7
94.3
92.5
ug/l
0.04
147
1096
131
1003
1.51
3.20
4.5
4.0
—
—
—
0
0
120
912
1.50
3.00
2.8
2.4
75.6
72.3
nmol/l
0.52
113
840
5
5
10.13
2.99
1.6
1.0
—
—
—
0
0
257
2285
1.58
2.90
4.8
4.1
1.9
1.9
mu/l
0.01
251
2110
16
65
2.54
2.83
2.1
1.6
—
—
—
0
0
32
175
1.92
2.80
6.8
10.5
0.6
1.0
mmol/l
0.36
25
138
18
78
2.38
2.80
1.5
1.6
0.0
0.0
iu/ml
—
5
15
125
970
1.47
2.78
9.6
7.6
1.2
1.2
mmol/l
0.65
107
844
16
66
2.50
2.75
1.5
1.3
1.2
1.2
g/l
0.11
16
61
28
148
1.98
2.70
7.1
11.7
120.8
124.6
g/l
0.47
28
143
26
134
2.02
2.69
2.6
1.6
—
—
—
0
0
134
1064
1.44
2.60
6.2
5.8
11.9
11.8
umol/l
0.01
129
1004
291
2692
1.72
2.51
13.2
7.9
27.0
26.4
u/l
0.13
286
2600
45
284
1.68
2.48
2.0
1.8
—
—
—
0
0
64
444
1.55
2.41
4.4
2.5
9541.8
6727.6
umol/l
0.11
55
398
6
13
4.68
2.28
3.5
3.9
—
—
—
0
0
220
1936
1.41
2.26
4.2
3.6
14.4
14.6
pmol/l
0.85
207
1749
67
479
1.50
2.19
4.8
4.0
15.6
12.3
mg/mmol
0.20
46
318
113
894
1.40
2.17
10.7
7.1
1.2
1.2
mmol/l
0.13
106
820
94
722
1.42
2.13
1.6
1.4
2.5
1.7
u/ml
0.24
27
184
8
25
3.25
2.11
1.1
1.3
—
—
—
0
0
34
212
1.67
1.98
6.6
5.6
—
—
—
0
0
29
173
1.74
1.97
2.3
2.4
11553.3
1521.3
u/l
—
6
68
5
11
4.60
1.95
5.6
1.9
13.9
19.7
ug/l
—
5
11
48
330
1.53
1.89
3.3
2.8
2203.3
465.9
ng/l
0.43
32
227
71
531
1.43
1.84
2.9
2.2
2.4
2.8
mg/l
0.95
64
437
194
1703
1.34
1.83
3.4
2.8
37.7
36.8
u/l
0.07
186
1622
5
12
4.21
1.83
1.0
1.0
—
—
—
0
0
5
12
4.21
1.83
1.0
1.6
1.5
2.1
mmol/l
—
5
12
76
577
1.41
1.82
4.0
2.8
0.1
0.3
e6/l
3.76
58
418
45
310
1.52
1.76
2.0
2.0
—
—
—
0
0
50
353
1.49
1.74
3.6
2.5
0.6
0.8
e6/l
0.36
30
199
15
75
2.05
1.72
1.3
2.0
—
—
—
0
0
7
25
2.84
1.66
1.3
1.8
—
—
—
0
0
5
14
3.61
1.62
14.0
2.4
33.8
28.2
%
—
5
14
24
146
1.69
1.55
2.0
2.6
79.6
76.7
ml/min/173m2
—
9
64
241
2211
1.34
1.54
3.8
3.6
—
—
—
0
0
5
15
3.37
1.53
2.0
3.6
2.7
2.9
nmol/l
—
5
15
7
27
2.63
1.52
3.3
1.7
—
—
—
0
0
51
375
1.43
1.46
2.1
2.1
—
—
—
0
0
6
22
2.76
1.44
3.7
1.9
—
—
—
0
0
87
703
1.32
1.40
1.5
1.7
95.9
94.4
pmol/l
0.11
47
381
10
47
2.16
1.35
2.8
1.9
—
—
—
0
0
27
177
1.57
1.34
25.1
11.8
1.1
1.2
inr
—
10
36
6
24
2.53
1.31
1.0
1.2
—
—
—
0
0
97
804
1.29
1.29
1.9
1.7
—
—
—
0
0
8
35
2.32
1.27
3.0
1.9
—
—
—
0
0
29
196
1.53
1.27
2.1
1.7
—
—
—
0
0
48
359
1.39
1.26
1.6
1.7
393.3
12579056.3
pmol/l
0.50
43
318
10
49
2.07
1.23
1.8
1.3
—
—
—
0
0
40
293
1.42
1.19
4.7
2.2
27.8
29.8
s
2.42
40
284
10
50
2.03
1.17
2.7
1.8
—
—
—
0
0
15
87
1.76
1.17
1.2
1.3
—
—
—
0
0
5
20
2.52
1.15
1.4
1.9
—
—
—
0
0
16
96
1.70
1.12
1.9
1.5
—
—
—
0
0
33
236
1.44
1.12
14.3
4.8
1.8
1.6
mmol/l
0.17
28
186
237
2207
1.27
1.12
4.2
3.4
5.7
5.6
mmol/l
0.29
227
2036
22
144
1.57
1.12
1.3
1.9
—
—
—
0
0
25
169
1.52
1.11
3.0
7.4
1.7
1.6
mmol/l
0.10
19
121
24
161
1.53
1.10
4.8
3.3
4.9
4.7
pmol/l
0.45
24
147
27
186
1.49
1.10
6.9
4.3
235.1
232.2
u/l
0.07
27
179
28
195
1.48
1.09
2.3
1.8
—
—
—
0
0
7
33
2.15
1.06
1.1
1.8
—
—
—
0
0
270
2562
1.30
1.05
18.6
10.8
39.2
40.6
%
1.55
209
2078
43
327
1.36
1.04
3.7
2.7
1.3
2.6
e6/l
1.15
23
175
5
22
2.29
1.03
1.2
1.0
—
—
—
0
0
7
34
2.08
1.03
3.7
1.9
—
—
—
0
0
16
99
1.65
1.02
6.6
10.5
92.7
94.6
%
0.50
16
99
13
77
1.72
0.96
1.4
1.3
—
—
—
0
0
237
2224
1.24
0.95
10.5
8.7
94.5
93.0
ml/min/173m2
0.38
186
1722
21
142
1.51
0.95
1.2
1.5
269.5
327.7
mu/l
0.73
21
133
7
37
1.91
0.94
2.1
1.3
—
—
—
0
0
6
27
2.24
0.94
1.0
1.1
—
—
—
0
0
62
506
1.28
0.93
2.9
2.0
—
—
—
0
0
28
202
1.42
0.93
1.1
1.3
47.2
147.0
iu/ml
2.26
14
91
29
211
1.41
0.92
15.3
4.4
5.5
4.8
kpa
0.77
29
206
8
44
1.84
0.86
3.0
2.3
—
—
—
0
0
25
180
1.42
0.85
16.7
8.3
24.8
25.1
mmol/l
0.29
25
180
22
155
1.45
0.83
4.9
5.1
64.8
71.2
ng/l
0.24
22
145
36
281
1.32
0.77
1.5
1.6
1113.6
1149.0
nmol/l
0.06
31
219
17
116
1.49
0.76
3.4
8.5
8.8
9.3
kpa
0.59
17
105
16
108
1.51
0.75
1.4
1.4
—
—
—
0
0
231
2187
1.19
0.73
4.2
3.2
1.3
1.2
mmol/l
0.35
225
2057
21
284
0.72
0.71
1.6
1.5
—
—
—
0
0
7
41
1.72
0.70
1.0
1.2
—
—
—
0
0
13
86
1.53
0.67
1.3
1.1
—
—
—
0
0
5
28
1.80
0.66
2.4
1.6
13.2
12.7
%
—
5
28
11
70
1.59
0.66
1.2
1.8
—
—
—
0
0
239
2278
1.18
0.65
4.3
3.4
1.4
1.5
mmol/l
0.37
232
2143
7
44
1.60
0.65
1.4
1.4
—
—
—
0
0
40
325
1.26
0.65
4.1
3.9
22.0
21.2
%
0.14
19
145
13
87
1.51
0.64
1.5
1.5
—
—
—
0
0
8
50
1.61
0.61
1.1
1.1
—
—
—
0
0
240
2294
1.17
0.61
4.4
3.5
4.7
4.7
mmol/l
0.29
233
2168
12
80
1.52
0.60
1.2
1.3
—
—
—
0
0
64
554
1.19
0.58
1.8
1.7
1.3
1.3
mmol/l
0.09
58
481
241
2317
1.15
0.51
4.6
3.7
2.8
2.8
mmol/l
0.30
234
2173
7
46
1.53
0.48
1.3
1.4
—
—
—
0
0
12
87
1.39
0.43
1.7
1.9
—
—
—
0
0
0
16
0.00
0.41
0.0
2.3
—
0.1
—
0
11
23
187
1.25
0.40
1.0
1.1
—
—
—
0
0
18
142
1.28
0.39
3.3
3.8
1.2
1.2
mmol/l
0.32
13
122
75
683
1.13
0.37
3.2
3.3
2.3
2.4
mmol/l
1.46
69
626
9
125
0.71
0.35
1.8
1.3
—
—
—
0
0
11
82
1.35
0.34
1.2
1.3
—
—
—
0
0
13
100
1.31
0.34
1.8
1.6
—
—
—
0
0
25
211
1.20
0.32
1.4
1.3
—
—
—
0
0
11
84
1.32
0.30
36.4
8.3
1.2
1.2
mg/l
0.10
11
79
10
128
0.77
0.27
1.5
1.5
—
—
—
0
0
9
74
1.22
0.25
1.0
1.1
—
—
—
0
0
9
74
1.22
0.25
1.0
1.1
—
—
—
0
0
11
87
1.27
0.24
1.6
1.6
158.8
203.5
u/ml
—
6
46
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
11
89
1.24
0.21
1.0
1.2
0.4
2.2
u/ml
—
6
44
0
13
0.00
0.21
0.0
1.2
—
98.4
—
0
13
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
6
48
1.25
0.20
1.0
1.2
—
10.8
—
0
10
11
91
1.22
0.18
1.5
1.6
—
—
—
0
0
11
130
0.84
0.16
1.1
1.6
2.5
2.6
mg/l
—
6
85
41
381
1.09
0.15
4.6
3.3
1975.5
891.0
ng/l
0.45
36
304
10
83
1.21
0.15
3.1
3.3
52.7
53.5
%
—
10
83
20
180
1.12
0.13
2.8
2.9
—
—
—
0
0
13
113
1.16
0.13
2.1
1.5
—
—
—
0
0
18
163
1.11
0.11
2.1
1.6
22.9
18.6
iu/l
0.22
18
139
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
5
45
1.11
0.10
1.2
3.4
—
0.3
—
0
25
47
450
1.05
0.08
1.5
1.4
—
—
—
0
0
7
67
1.05
0.08
1.9
1.4
—
—
—
0
0
10
112
0.89
0.07
1.5
1.4
—
—
—
0
0
10
112
0.89
0.07
1.5
1.4
—
—
—
0
0
10
112
0.89
0.07
1.5
1.4
—
—
—
0
0
10
112
0.89
0.07
1.5
1.4
—
—
—
0
0
11
122
0.90
0.07
1.5
2.0
15.4
34.6
u/ml
1.52
11
117
9
88
1.02
0.07
1.8
1.8
—
—
—
0
0
16
149
1.08
0.05
1.4
1.4
—
—
—
0
0
23
220
1.05
0.03
3.3
3.3
33.1
31.2
%
0.35
16
147
20
191
1.05
0.03
3.2
2.9
0.2
0.2
g/l
0.21
20
178
23
222
1.04
0.02
1.6
1.5
—
—
—
0
0
15
143
1.05
0.01
2.0
1.7
—
—
—
0
0
66
654
1.01
0.00
2.9
2.4
—
—
—
0
0
23
233
0.99
0.00
2.3
2.7
0.7
0.8
ug/l
0.04
15
148
60
604
0.99
0.00
2.8
2.2
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
0.00
0.0
3.8
—
128.7
—
0
9
0
9
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
1.7
—
0
6
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.7
—
—
—
0
0
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint M13_TRANSSYNOVITIS and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| M13_TRANSSYNOVITIS | 1.188 [0.89, 1.59] | 0.244 |
| Birth year | 0.993 [0.98, 1.0] | 0.098 |
During the follow-up period (1.1.1998 — 31.12.2019), 53 out of 1551 females with M13_TRANSSYNOVITIS died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| M13_TRANSSYNOVITIS | 1.195 [0.91, 1.56] | 0.196 |
| Birth year | 0.989 [0.98, 1.0] | 0.024 |
During the follow-up period (1.1.1998 — 31.12.2019), 71 out of 2694 males with M13_TRANSSYNOVITIS died.
Mortality risk
Mortality risk for people of age
years, who have M13_TRANSSYNOVITIS.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.096% | 0.247% |
| 5 | 0.579% | 1.482% |
| 10 | 1.456% | 3.667% |
| 15 | 2.989% | 7.022% |
| 20 | 5.127% | 11.837% |
Relationships between endpoints
↥Index endpoint: M13_TRANSSYNOVITIS – Transient synovitis
GWS hits: 1
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data